A woman who feared she would not live to see her son turn 13 after being diagnosed with cancer has defied the prognosis and ...

Medically reviewed by Marla Anderson, MDMultiple myeloma is a rare type of blood cancer that forms in plasma cells, a white ...

Arcellx's anito-cel shows promising efficacy and safety in multiple myeloma. Read why I maintain my hold rating for ACLX ...

The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory ...

AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...

Delayed diagnosis causes a significant disadvantage for Hungarian patients adding cost and complexity to the already stretched healthcare system.

A groundbreaking study recently published in the New England Journal of Medicine has shown that a combination of two existing ...

A CD38 monoclonal antibody, Sarclisa binds to a specific epitope on the CD38 receptor on myeloma cells, ultimately inducing ...

Paris: Sanofi has announced that the National Medical Products Administration (NMPA) in China has approved Sarclisa, an ...

China NMPA approves Sanofi’s Sarclisa in combo with pomalidomide and dexamethasone to treat adult patients with R/R multiple myeloma: Paris Tuesday, January 14, 2025, 10:00 Hrs ...

AbbVie and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd., entered an option to license agreement to ...

In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer, in ...